Virologic and Immunologic Parameters that Predict Clinical Response of AIDS-Associated Kaposi's Sarcoma to Highly Active Antiretroviral Therapy
- 1 October 2001
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 117 (4) , 858-863
- https://doi.org/10.1046/j.0022-202x.2001.01465.x
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS Patients on highly active antiretroviral therapyAIDS, 2000
- Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patientsAIDS, 2000
- Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi‚s sarcomaAIDS, 1999
- Infection of Circulating CD34+ Cells by HHV-8 in Patients with Kaposi’s SarcomaJournal of Investigative Dermatology, 1999
- Epstein-Barr Virus–Infected Resting Memory B Cells, Not Proliferating Lymphoblasts, Accumulate in the Peripheral Blood of Immunosuppressed PatientsThe Journal of Experimental Medicine, 1999
- The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcomaBritish Journal of Dermatology, 1999
- Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatmentAIDS, 1998
- HHV8 and Kaposi's sarcoma: a time cohort study.Molecular Pathology, 1997
- Survival of European patients with Kaposiʼs sarcoma as AIDS-defining condition during the first decade of AIDSAIDS, 1997
- Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee.Journal of Clinical Oncology, 1989